Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 291

The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.

α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies

Open access
Henderson, Michael X., Trojanowski, John Q., Lee, Virginia M.-Y.·2019·Neuroscience Letters

Abstract

Over 20 years ago, the synaptic protein alpha-synuclein was identified as the primary component of the Lewy bodies (LBs) that are a sine qua non of Parkinson’s disease (PD). Since that time, extensive research has demonstrated that alpha-synuclein pathology is not only a hallmark of PD, but can also cause neuronal dysfunction and death. Detailed staging of alpha-synuclein pathology in the brains of patients has revealed a progressive pattern of pathology that correlates with the symptoms of disease. Early in the disease course, PD patients exhibit motor dysfunction, and alpha-synuclein pathology at this stage is primarily found in regions controlling motor function. At later stages of disease as patients’ cognitive function deteriorates, alpha-synuclein pathology can be found in cortical structures responsible for higher cognitive processing. The stereotypical progression of alpha-synuclein pathology through the brain over time suggests that there may be a physical transmission of pathological alpha-synuclein from one area of the brain to another. The transmission hypothesis posits that an initial seed of pathological alpha-synuclein in one neuron may be released and taken up by another vulnerable neuron and thereby initiate pathological misfolding of alpha-synuclein in the recipient neuron. In recent years, convergent evidence from various studies has indicated that pathological protein transmission can occur in the human brain. Cell and animal models based on the transmission hypothesis have shown not only that pathological alpha-synuclein can be transmitted from cell-to-cell, but that this pathology can lead to neuronal dysfunction and degeneration. The alpha-synuclein transmission hypothesis has profound implications for treatment of what is currently an intractable neurodegenerative disease. In this review, we explore the evidence for cell-to-cell transmission of pathological alpha-synuclein, the current understanding of how pathological alpha-synuclein can move to a new cell and template misfolding, and the therapeutic implications of alpha-synuclein transmission.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neulet.2019.134316

Cites

158 of 158 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

5 retracted

Show all 158 references

Cited by

See all 291

Metadata

Authors
Henderson, M. X., Trojanowski, J. Q., & Lee, V. M.-Y.
Venue
Neuroscience Letters
Publisher
Elsevier BV
Published
2019-09
Volume
709
Pages
134316
ISSN
0304-3940 (ISSN-L)
OpenAlex
W2948657684
Cited by
291
References
158
FWCI
18.00
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies. https://app.cochat.ai/papers/10.1016/j.neulet.2019.134316
The paper
Henderson, M. X., Trojanowski, J. Q., & Lee, V. M.-Y. (2019). α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies. Neuroscience Letters. https://doi.org/10.1016/j.neulet.2019.134316

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.